Consumer Industry Reports

Researchers Hail Promise Of First Potential Ebola Treatments In DRC Trial


Reportedly, the scientists are a step near to finding the first successful treatments for the life-threatening Ebola hemorrhagic fever following two potential drugs demonstrated potential survival outcomes in a clinical trial in Congo. Two investigational drugs—a monoclonal antibody known as mAb114 and Regeneron’s REGN-EB3—were developed by using antibodies from patients suffering from Ebola. The drugs showed “better” outcomes in patients in a test of four promising treatments being carried during the second-largest Ebola outbreak globally in history, now entering in its second year in DRC (Democratic Republic of Congo).

One of the scientists co-leading the trial, Anthony Fauci stated that the drugs increased the survival rates more from the disease compared to two other treatments being carried—Remdesivir (by Gilead Sciences) and ZMapp (by Mapp Biopharmaceutical)—and those products would be now dropped. In a telebriefing, Anthony Fauci—Director of the U.S. NIAID (National Institute of Allergy and Infectious Diseases)—said the outcome was good news for the fight against Ebola. Reportedly, this fatal disease has been spreading across eastern Congo from August 2018 in an outburst that is presently the second largest, killing minimum 1,800 people. The attempts to control it have been obstructed by armed force violence and some local opposition to outside help.

On a related note, recently, it was reported that an existing antiparasitic drug can provide treatment for Ebola. In the middle of worsening Ebola outburst in DRC (also presently spreading across Rwanda), recent research suggested that a current, FDA (Food and Drug Administration)-approved drug called nitazoxanide can potentially help in controlling this highly contagious and deadly infection. In meticulous trials in human cells, conducted by Boston Children’s Hospital, the drug considerably amplified immune reactions to Ebola and hindered Ebola replication.

Leave A Reply

Your email address will not be published.